Literature DB >> 2562956

Progesterone interacts with P-glycoprotein in multidrug-resistant cells and in the endometrium of gravid uterus.

C P Yang1, S G DePinho, L M Greenberger, R J Arceci, S B Horwitz.   

Abstract

P-Glycoprotein (P-GP) plays a pivotal role in maintaining the multidrug-resistant (MDR) phenotype. This membrane glycoprotein is overproduced in MDR cells and the endometrium of the mouse gravid uterus (Arceci, R.J., Croop, J.M., Horwitz, S.B., and Housman, D. (1988) Proc. Natl. Acad. Sci. U.S.A. 85, 4350-4354). This latter observation and an interest in endogenous substrates for P-GP led to a study of the interaction of steroids with P-GP found in the endometrium of the mouse gravid uterus and in MDR cells derived from the murine macrophage-like cell J774.2. [3H]Azidopine labeling of P-GP from these two sources was inhibited by various steroids, particularly progesterone. Progesterone also markedly inhibited [3H]vinblastine binding to membrane vesicles prepared from MDR cells, enhanced vinblastine accumulation in MDR cells, and increased the sensitivity of MDR cells to vinblastine. In addition, we have demonstrated that the hydrophobicity of a steroid is important in determining its effect on inhibition of drug binding to P-GP. It is concluded that progesterone, a relatively nontoxic endogenous steroid, interacts with P-GP and is capable of reversing drug resistance in MDR cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562956

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  47 in total

Review 1.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Genetic basis of multidrug resistance of tumor cells.

Authors:  S E Kane; I Pastan; M M Gottesman
Journal:  J Bioenerg Biomembr       Date:  1990-08       Impact factor: 2.945

3.  Structure and expression of the human MDR (P-glycoprotein) gene family.

Authors:  J E Chin; R Soffir; K E Noonan; K Choi; I B Roninson
Journal:  Mol Cell Biol       Date:  1989-09       Impact factor: 4.272

4.  Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3).

Authors:  B I Florea; I C van der Sandt; S M Schrier; K Kooiman; K Deryckere; A G de Boer; H E Junginger; G Borchard
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

5.  Modulation of mitomycin C-induced multidrug resistance in vitro.

Authors:  R T Dorr; J D Liddil
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Reversal of the human and murine multidrug-resistance phenotype with megestrol acetate.

Authors:  L Wang; C P Yang; S B Horwitz; P A Trail; A M Casazza
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

7.  Evaluation of 2,6-diamino-N-([1-(1-oxotridecyl)-2-piperidinyl]methyl)- hexanamide (NPC 15437), a protein kinase C inhibitor, as a modulator of P-glycoprotein-mediated resistance in vitro.

Authors:  E C Sha; M C Sha; S H Kaufmann
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

8.  Non-glucocorticoid steroid analogues (21-aminosteroids) sensitize multidrug resistant cells to vinblastine.

Authors:  I Abraham; C L Wolf; K E Sampson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 9.  Hormone response in ovarian cancer: time to reconsider as a clinical target?

Authors:  Francesmary Modugno; Robin Laskey; Ashlee L Smith; Courtney L Andersen; Paul Haluska; Steffi Oesterreich
Journal:  Endocr Relat Cancer       Date:  2012-11-09       Impact factor: 5.678

10.  Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding.

Authors:  Omar Alqawi; Susan Bates; Elias Georges
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.